Form 4: Inmune Bio CEO's Stock Options Repriced to $1.50

Inmune Bio, Inc. announced the repricing of CEO David Moss's stock options to $1.50 per share, aligning with the current market price.

Summary

• Inmune Bio, Inc. (INMB) stockholders approved a one-time repricing of certain outstanding stock options on November 18, 2025.
• The per share exercise price of these "Repriced Options" was reduced to $1.50, which was the closing price of the company's common stock on The Nasdaq Capital Market on the repricing date.
• The repricing affects options granted under the Issuer's 2017, 2019, and Second Amended and Restated 2021 Stock Incentive Plans.
• All other terms and conditions of the repriced options, including vesting schedules and term, remain unchanged.
• For CEO David J. Moss, a total of 1,477,999 stock options were repriced from various higher exercise prices (ranging from $3.91 to $24.82) down to $1.50 per share.

Sentiment

Score: 4

Explanation: The repricing of stock options, while potentially re-incentivizing management, generally reflects past poor stock performance where options became 'underwater'. This can be viewed negatively by shareholders due to potential dilution and a perceived transfer of value, despite shareholder approval. It's a necessary step to retain talent but signals underlying stock price challenges.

Positives

• Repricing options to the current market price ($1.50) can re-incentivize management and employees whose options were significantly "underwater" (exercise price higher than current stock price).
• Aligns management's financial interests more closely with current shareholder value, potentially motivating efforts to increase the stock price from its current level.
• The repricing was approved by the Issuer's stockholders, indicating shareholder consent for this action.

Negatives

• Stock option repricing can be viewed negatively by some investors as it effectively transfers value from shareholders to option holders, especially if the original options were granted at much higher prices.
• It can signal a lack of confidence in the company's ability to reach previous stock price levels, or that the company's stock has performed poorly.
• While not direct dilution, it increases the likelihood of future dilution if these options are exercised at a lower price, potentially increasing the number of outstanding shares at a lower cost to the option holder.

Risks

• The act of repricing options implies a risk that the original options were underwater, suggesting past stock underperformance.
• Potential for negative investor perception regarding management compensation practices if not clearly justified.

Future Outlook

The repriced stock options become exercisable in accordance with their original vesting schedules, subject to the reporting person's continued service with the Issuer. This implies a future commitment and potential exercise of these options.

Management Comments

• "Effective as of November 18, 2025 (the 'Repricing Date'), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options... which reduced the per share exercise price of each Repriced Option to $1.50, representing the closing price of the Issuer's common stock on The Nasdaq Capital Market on the Repricing Date."
• "Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect."
• "This stock option award was issued pursuant to the 2017 Plan, 2019 Plan and/or the 2021 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date."

Industry Context

Stock option repricing often occurs in industries, particularly biotechnology or high-growth tech, where stock prices can be volatile or experience significant declines. When options go "underwater" (exercise price is above the current market price), they lose their incentive value. Repricing aims to restore this incentive, retain key talent, and re-align management's interests with current shareholder value. This is a common practice, though often met with mixed reactions from investors.

Comparison to Industry Standards

• Repricing options to the current market price is a common method to restore incentive value for underwater options, particularly in volatile sectors like biotech where stock performance can fluctuate significantly based on clinical trial results or regulatory approvals.
• The approval by stockholders is a key governance aspect, as repricing without shareholder approval can be viewed more negatively.
• The specific exercise price of $1.50, being the closing market price, is a standard approach for repricing to ensure fairness relative to current market conditions.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised. May view the repricing negatively as it reflects past stock underperformance and transfers value to option holders. However, shareholder approval suggests a belief that it's necessary for management retention and future performance.
• Employees (Option Holders): Re-incentivized as their options, previously underwater, now have value, potentially improving morale and retention.
• Management (David Moss): Directly benefits from the repricing, restoring the incentive value of his equity compensation.

Next Steps

• The repriced options will become exercisable according to their original vesting schedules.
• David Moss's continued service with Inmune Bio, Inc. is required for the options to vest.
• Potential future exercise of these options by David Moss.

Key Dates

Recommendation

The repricing of stock options for the CEO, while approved by shareholders, indicates significant past stock underperformance. This action is typically taken to re-incentivize management and retain talent when options are underwater. While it addresses a critical issue for executive motivation, it doesn't fundamentally change the company's operational or financial prospects as disclosed in this Form 4. Investors should hold and monitor future operational performance and strategic developments rather than reacting solely to this compensation adjustment. The repricing itself is a neutral to slightly negative signal regarding past performance, but a positive one for future management alignment.

Keywords

Inmune Bio, INMB, stock option repricing, Form 4, SEC filing, insider transaction, executive compensation, David Moss, stock incentive plan, equity compensation, corporate governance